Lunit’s Breast Cancer AI More Accurate than Radiologist Reviews

Lunit’s study of 55,579 mammograms showed an increased cancer detection rate and a lower patient recall rate using the company’s Insight MMG breast cancer artificial (AI) solution than a team of two radiologists, the South Korea-headquartered company reported.

Insight MMG is an FDA-approved and CE certified AI tool that analyzes mammograms to provide more accurate diagnosis. The large-scale study, conducted From April 1, 2021, to June 9, 2022, used mammography radiographs from medical institutions around the world.

The study was designed with results reviewed by three combinations of reviewer: two radiologists, Lunit AI plus one radiologist and AI alone. Study results showed that Insight MMG, when combined with a single radiologist, can detect more cancers compared to two radiologists, the company said.